Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)
Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%
Castle Biosciences total assets
Total assets on the balance sheet at the end of each period.
Castle Biosciences's total assets was $579.41M at Sep 30, 2026. For fiscal 2025 it was $578.56M, up 8.9% from the year before. The highest annual figure on record is $578.56M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $578.56M | +8.9% |
| FY2024 | Dec 31, 2024 | $531.24M | +17.2% |
| FY2023 | Dec 31, 2023 | $453.34M | +1.3% |
| FY2022 | Dec 31, 2022 | $447.33M | -3.3% |
| FY2021 | Dec 31, 2021 | $462.57M | +5.3% |
| FY2020 | Dec 31, 2020 | $439.33M | +266.9% |
| FY2019 | Dec 31, 2019 | $119.75M | +434.5% |
| FY2018 | Dec 31, 2018 | $22.41M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $579.41M | +3.0% |
| Q2 FY2026 | Jun 30, 2026 | $561.18M | +3.0% |
| Q1 FY2026 | Mar 31, 2026 | $547.81M | +9.2% |
| Q4 FY2025 | Dec 31, 2025 | $578.56M | +8.9% |
| Q3 FY2025 | Sep 30, 2025 | $562.79M | +9.4% |
| Q2 FY2025 | Jun 30, 2025 | $544.73M | +11.8% |
| Q1 FY2025 | Mar 31, 2025 | $501.72M | +9.4% |
| Q4 FY2024 | Dec 31, 2024 | $531.24M | +17.2% |
| Q3 FY2024 | Sep 30, 2024 | $514.57M | +18.0% |
| Q2 FY2024 | Jun 30, 2024 | $487.31M | +14.6% |
| Q1 FY2024 | Mar 31, 2024 | $458.51M | +7.4% |
| Q4 FY2023 | Dec 31, 2023 | $453.34M | +1.3% |
| Q3 FY2023 | Sep 30, 2023 | $436.02M | -4.8% |
| Q2 FY2023 | Jun 30, 2023 | $425.40M | -7.2% |
| Q1 FY2023 | Mar 31, 2023 | $426.89M | -3.9% |
| Q4 FY2022 | Dec 31, 2022 | $447.33M | -3.3% |
| Q3 FY2022 | Sep 30, 2022 | $457.81M | +5.6% |
| Q2 FY2022 | Jun 30, 2022 | $458.38M | +5.2% |
| Q1 FY2022 | Mar 31, 2022 | $444.43M | +1.6% |
| Q4 FY2021 | Dec 31, 2021 | $462.57M | +5.3% |
| Q3 FY2021 | Sep 30, 2021 | $433.69M | +106.1% |
| Q2 FY2021 | Jun 30, 2021 | $435.53M | +116.1% |
| Q1 FY2021 | Mar 31, 2021 | $437.33M | +263.7% |
| Q4 FY2020 | Dec 31, 2020 | $439.33M | +266.9% |
| Q3 FY2020 | Sep 30, 2020 | $210.39M | +85.9% |
| Q2 FY2020 | Jun 30, 2020 | $201.55M | +504.4% |
| Q1 FY2020 | Mar 31, 2020 | $120.26M | +436.7% |
| Q4 FY2019 | Dec 31, 2019 | $119.75M | – |
| Q3 FY2019 | Sep 30, 2019 | $113.20M | – |
| Q2 FY2019 | Jun 30, 2019 | $33.35M | – |
| Q4 FY2018 | Dec 31, 2018 | $22.41M | – |
See a number that looks wrong?